Get started
Cumberland Pharmaceuticals Inc.Cumberland Pharmaceuticals Inc.Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Options

CPIX trade ideas

CPIX – 30-Min Long Trade Setup!📌 🔹 Asset: Cumberland Pharmaceuticals Inc. (CPIX) 🔹 Timeframe: 30-Min Chart 🔹 Setup Type: Descending Triangle Breakout Long Trade 📌 Trade Plan (Long Position) ✅ Entry Zone: Above $5.36 (Breakout Confirmation) ✅ Stop-Loss (SL): Below $4.74 (Break of Support & Trendline) 🎯 Take Profit Targets 📌 TP1: $6.13 (First Resistance Level) 📌 TP2: $7.23 (Final Target – Extended Bullish Move) 📊 Risk-Reward Ratio Calculation 📈 Risk (SL Distance): $5.36 - $4.74 = $0.62 risk per share 📈 Reward to TP1: $6.13 - $5.36 = $0.77 (1.24 R/R) 📈 Reward to TP2: $7.23 - $5.36 = $1.87 (3.02 R/R) 🔍 Technical Analysis & Strategy 📌 Descending Triangle Breakout Setup: CPIX has been consolidating in a downward-sloping triangle, with a breakout expected at $5.36. 📌 Trendline & Support Bounce: The price is attempting to break out of the pattern, indicating buyer accumulation. 📌 Breakout Confirmation: A strong bullish candle above $5.36 with increasing volume would confirm momentum. 📌 Momentum Shift Expected: If price holds above $5.36, a rally toward $6.13 (TP1) and $7.23 (TP2) is likely. 📊 Key Support & Resistance Levels 🟢 $4.74 – Strong Support / Stop-Loss Level 🟡 $5.36 – Entry / Breakout Level 🔴 $6.13 – First Resistance / TP1 🟢 $7.23 – Final Target / TP2 🚀 Trade Execution & Risk Management 📊 Volume Confirmation: Ensure strong buying volume above $5.36 before entering. 📈 Trailing Stop Strategy: Move SL to entry ($5.36) after TP1 ($6.13) is hit. 💰 Partial Profit Booking Strategy: ✔ Take 50% profits at $6.13, let the rest run to $7.23. ✔ Adjust Stop-Loss to Break-even ($5.36) after TP1 is reached. ⚠️ Fake Breakout Risk ❌ If price fails to hold above $5.36 and breaks back down, it could indicate a false breakout—exit early. ❌ Wait for a strong candle close above $5.36 for confirmation before entering aggressively. 🚀 Final Thoughts ✔ Bullish Setup – Holding above $5.36 could lead to higher targets. ✔ Momentum Shift Possible – Watch for volume confirmation. ✔ Favorable Risk-Reward Ratio – 1:1.24 to TP1, 1:3.02 to TP2. 💡 Stick to the plan, manage risk, and trade smart! 🚀🏆 🔗 #StockTrading #CPIX #CumberlandPharmaceuticals #BreakoutTrade #TechnicalAnalysis #MarketTrends #ProfittoPath #DayTrading #MomentumStocks #SwingTrading #TradingView #LongTrade #TradeSmart #RiskManagement #StockBreakout #Investing #StockAlerts #ChartAnalysis 🚀📈
NASDAQ:CPIXLong
by ProfittoPath
$CPIXCumberland Pharmaceuticals shares are trading higher after the company announced the FDA approved expanded labeling for Caldolor to now include use in pre-operative administration. Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ injection, for the treatment of certain serious bacterial infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. The company markets and sells its products through sales representatives and district managers. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
NASDAQ:CPIXLong
by BADQOMOCAWGOWLD